Pipeline Breakdown: Merck & Co. Inc.

Merck (NYSE: MRK  ) recently held its analyst day, updating analysts and investors listening in on its pipeline. While there weren't any major announcements -- no high-profile clinical trial results were announced -- there were a few tidbits that investors should pay attention to.

In the video below, senior biotech specialist Brian Orelli and health-care analyst David Williamson highlight a few of the crumbs that Merck left for investors.

MK-3475, Merck's PD-1 immuno-oncology drug, which is currently under review by the Food and Drug Administration for use in melanoma in patients that have failed Bristol-Myers Squibb's (NYSE: BMY  ) Yervoy, is in a head-to-head trial against Yervoy that should read out in the second half of the year. Meanwhile, Bristol-Myers Squibb is testing its competitor MK-3475 in combination with Yervoy, which could be more successful than MK-3475 on its own.

Filing for Merck's odanacatib for osteoporosis was delayed last year to collect more data. The pharma giant now says it'll file in the second half of this year, but the drug has some safety issues and will enter a crowded space with generic osteoporosis drugs.

Finally, Merck announced that it plans to start a trial testing its hepatitis C drugs in combination with Gilead Sciences' (NASDAQ: GILD  ) Sovaldi. The hope is that the regimen will be effective in as little as four weeks, reducing the treatment time of Gliead's Sovaldi regimen.

Looking for dividend ideas?
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2959712, ~/Articles/ArticleHandler.aspx, 11/28/2014 7:37:16 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement